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Introduction
Hepatitis C virus (HCV) in pregnancy is relatively
uncommon, with most studies reporting a prevalence
of < 5% [1–3]. Reports of fetal complications in moth-
ers infected with HCV are also limited and the risk 
of mother-to-infant transmission varies widely. Second
trimester perinatal HCV infection with possible cyto-
megalovirus (CMV) coinfection that is associated with
fetal ascites is a rare event; fetal therapy resulting in a
successful outcome has not been reported. We report
a case of early second trimester maternal HCV infec-
tion associated with fetal ascites, which was treated
with fetal paracentesis, resulting in a term liveborn
infant with anti-HCV seropositivity. Perinatal trans-
mission and perinatal outcome associated with HCV
and CMV infections are also discussed.
Case Report
A 26-year-old, gravida 1, para 0, woman with no 
history of hepatitis, blood transfusions or significant
past medical or surgical history presented for prenatal
care starting in the first trimester. Her gynecologic 
history was significant for a total of three past sexual
partners, the last one being her current husband. She
complained of anorexia and malaise of 1-week duration
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SUMMARY
Objective: To present the first reported case of early second trimester maternal hepatitis C virus (HCV) associ-
ated with fetal ascites, which was treated with fetal paracentesis, and resulted in a successful outcome of a term
liveborn infant with anti-HCV seropositivity.
Case Report: A 26-year-old primigravida woman was diagnosed with acute HCV infection at 17 weeks of gesta-
tion. Ultrasound (US) at 23 weeks showed significant fetal ascites and echogenic bowel, and fetal viral infection
was suspected. Maternal serum was positive for high HCV-RNA titers and cytomegalovirus (CMV) IgG.
Amniocentesis, cordocentesis and therapeutic fetal paracentesis were performed at 23 weeks. Fetal karyotype
was 46,XX. Cord blood showed anti-HCV positivity and HCV-RNA titer < 10. Amniotic fluid was anti-HCV and
CMV IgG positive. US at 27 weeks showed complete resolution of fetal ascites. A healthy 2,976 g female baby
was delivered at 37 weeks, with anti-HCV seropositivity, high HCV-RNA titers, CMV IgG positive, IgM negative
and normal liver function tests at the 1-month follow-up.
Conclusion: Second trimester perinatal HCV infection with possible CMV coinfection associated with fetal
ascites is a rare event. Fetal therapy resulting in a successful outcome has not been reported. Prompt fetal ther-
apy with paracentesis in this case led to the delivery of a healthy term liveborn baby with anti-HCV seropositivity.
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at 17 weeks’ gestation. She was found to have jaundice
and had elevated liver function tests (LFTs) (aspartate
aminotransferase, 333 IU; alanine aminotransferase,
753 IU) with total bilirubin of 4.9 mg/mL. At that time,
she reported that her husband was anti-HCV seroposi-
tive due to blood transfusion after an operation during
infancy. Hepatitis tests showed positive anti-HCV anti-
bodies but were negative for hepatitis A and B. She
declined testing for human immunodeficiency virus.
She was asymptomatic by 21 weeks’ gestation.
Ultrasound (US) at 21 weeks showed an appropri-
ate for gestational age sized 519 g female fetus with
ascites but normal amniotic fluid volume (AFV). Level II
US at 23 weeks showed a 717 g fetus with normal AFV,
significant fetal ascites and fetal echogenic bowel,
with an umbilical artery systolic/diastolic ratio of 3:1
(Figures 1 and 2). Fetal viral infection was suspected
due to the maternal history of acute HCV infection
during pregnancy. The option of termination of preg-
nancy was discussed and possible adverse fetal out-
comes were reviewed with the patient; she decided to
continue with the pregnancy. Amniocentesis, cordocen-
tesis and therapeutic fetal paracentesis were performed
at 23 weeks. Fetal karyotype was 46,XX. Amniotic fluid
was positive for anti-HCV antibodies and CMV IgG
but negative for CMV IgM and toxoplasmosis IgG and
IgM. Fetal paracentesis was performed due to concern
that pulmonary hypoplasia could develop from the
marked upward displacement of the diaphragm. It was
performed using a 22-gauge spinal needle with aspira-
tion of 50 mL of straw-colored ascitic fluid. Fetal ascitic
fluid was positive for anti-HCV antibody and CMV IgG
(90.6 Au/mL) but not CMV IgM. The ascitic fluid was
not evaluated for cell counts or biochemistry. The lim-
ited amount of cord blood obtained was positive for
anti-HCV antibodies with an HCV-RNA titer < 10. The
maternal serum HCV-RNA titer on the same day was
1,330,000 copies/mL (HCV-RNA type 1b) and posi-
tive for CMV IgG (250 Au/mL) but not IgM.
Follow-up US at 25 weeks showed minimal ascites,
with complete resolution of fetal ascites by 27 weeks’
gestation. However, minimal fetal echogenic bowel was
still present. Between 28 and 34 weeks, maternal LFTs
were between 100 and 300 IU. The maternal HCV-RNA
titer increased to 9,410,000 copies/mL at 34 weeks of
gestation. US at this time showed a normal size 2,243 g
fetus with normal AFV. There was no evidence of fetal
ascites or other major fetal structural anomalies.
The patient delivered at 37 weeks by cesarean 
section due to fetal malpresentation following spon-
taneous rupture of membranes and labor. A 2,976 g
female baby was delivered, with Apgar score of
91105. At the 1-month neonatal visit, the infant had
hemoglobin of 9.9 mg/mL, was CMV IgG positive
(239 Au/mL) but IgM negative, had normal LFTs and
was anti-HCV seropositive with a very high HCV-RNA
titer of 17,883,600 copies/mL. The infant appeared to
be healthy and had a normal physical examination.
Maternal follow-up at 2.5 months postpartum showed
an HCV-RNA titer of 557,078 copies/mL. Her husband
was tested and was found to be carrying the same type
of HCV-RNA (type 1b). Both the patient and infant
were scheduled to return for follow-up examinations
and laboratory tests at 6 months after delivery.
Discussion
Hepatitis C is a single-stranded RNA virus of the
Flaviviridae family that is transmitted via infected
blood or blood products, or sexually transmitted via
saliva, vaginal secretions or semen. Although more
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Figure 1. Longitudinal view at 23 weeks of gestation shows
fetal ascites and echogenic bowel.
Figure 2. Transverse view of the abdomen at 23 weeks of
gestation shows ascites. Largest diameter of anteroposterior
ascitic fluid collection is 1.8 cm.
prevalent in intravenous drug users, hemophiliacs and
those with high-risk sexual behavior, only half of anti-
HCV-positive persons have risk factors [1]. This patient
likely contracted HCV from her husband during preg-
nancy as they both carry the same type of HCV-RNA
and she has no other known risk factors or past history
of hepatitis.
HCV in pregnancy is relatively uncommon, with
most studies reporting a prevalence < 5% [2,3]. The
prevalence of HCV in pregnancy in Taiwan is unknown
as there is no routine screening for it during prenatal
care. Antiviral treatment for HCV is usually not given
during pregnancy. Currently, there are no known meth-
ods for the prevention of HCV transmission at birth.
Perinatal transmission can occur while the fetus is 
in utero or during the intrapartum period, with an esti-
mated reported rate of 0% to as high as 18% [4–7],
and an average reported rate of approximately 5%
[8–10]. Dunn et al [11] reported on the uncertainty
associated with the diagnosis of HCV in children born
to HCV-infected mothers, which is currently based on
serologic assays and HCV-RNA measurement by poly-
merase chain reaction (PCR), due to lack of data
about the age distribution of loss of maternal antibod-
ies and specificity of PCR at different ages. Currently
available data suggest that the presence of HCV-RNA
in the neonate confirms vertical transmission of HCV
and that passively transmitted maternal anti-HCV
antibodies are detected in most of the neonates, per-
sisting for 6–18 months [12,13]. Increased rates of
vertical transmission have been noted in women with
high HCV-RNA titers or concurrent HIV infection [5],
drug use, viral genotype and vaginal deliveries [10].
This patient was viremic throughout the latter half of
her pregnancy, with very high titers of HCV-RNA, thus
increasing the chance of HCV transmission or infec-
tion of her fetus. Furthermore, the infant had a remark-
ably high HCV-RNA titer of 17,883,600 copies/mL at
her 1-month neonatal follow-up visit.
We did not test for either maternal or fetal/neona-
tal HCV IgM in this case. This is because, although
there are different diagnostic techniques for detecting
HCV, the detection of specific IgG against HCV by
means of enzyme immunoassays is the most practical
method for diagnosing infection by this virus [14].
HCV-RNA detection using PCR can also be used for
the diagnosis of HCV. The finding of HCV-RNA titer
< 10 in antepartum fetal cord blood implies that there
may not be active replication of HCV at the time when
the sample was obtained. However, data suggest that
mother-to-infant transmission of HCV is possible only
in the case of HCV-RNA positive mothers [15], as in
this case. Furthermore, the transmission of HCV from
mother to infant appears to correlate with the level of
maternal circulating viral load [16]. Given the pres-
ence of both anti-HCV antibodies, high maternal and
later neonatal HCV-RNA viral loads, and the same
HCV type Ib genotype, vertical transmission of HCV
can be confirmed in this case.
We postulate that the fetus acquired HCV in utero
given the timing and severity of the second trimester
maternal acute HCV infection, high HCV-RNA levels
and coincidental finding of fetal ascites. Rupture of
the amniotic membrane may have exposed the fetus to
further HCV viral loads.
This patient’s case was further complicated by the
question of concomitant CMV infection, with positive
CMV IgG but negative CMV IgM noted during her
pregnancy. The presence of CMV IgG in the fetus/infant
and maternal blood has been reported to be of limited
value given the high prevalence of CMV IgG in women
of childbearing age, and preexisting maternal CMV
immunity has been reported to strongly reduce perinatal
transmission [16]. Clinically apparent sequelae from
congenital CMV infections are less often associated with
recurrent maternal infection reactivation than with
primary infections. As both maternal and fetal CMV IgM
were negative in this case, we do not highly suspect
congenital CMV coinfection, although we cannot defini-
tively rule it out. Congenital fetal chylous ascites was not
suspected as it has been reported to be usually associ-
ated with polyhydramnios [17], which was not present
in this case. We believe that HCV played a major role in
the fetal ascites in this case, given the timing of maternal
acute clinical hepatitis infection, maternal high viral load
and subsequent sonographic findings of fetal ascites.
The fact that the maternal serum, fetal ascitic fluid and
infant’s blood all tested negative for CMV IgM antibod-
ies, in conjunction with similar levels of CMV IgG being
found in both maternal and infant sera, made passive
transplacental transfer of CMV IgG a more likely possi-
bility. Longer follow-up of the infant, along with serial
serologic testing for CMV and HCV antibodies and
HCV-RNA levels are required to clarify this issue.
In conclusion, second trimester maternal HCV
infection associated with fetal ascites is a rare event;
fetal therapy in the second trimester resulting in a suc-
cessful outcome has not been reported. This patient
had acute HCV infection in the second trimester and
subsequently developed fetal ascites. The high neona-
tal HCV viral load points to HCV playing a possible
major role in the neonate’s condition. Prompt fetal
therapy with paracentesis contributed to early resolu-
tion of the fetal ascites, resulting in the delivery of a
term liveborn infant with normal Apgar scores and
anti-HCV seropositivity.
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